Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that the conditions, including the minimum tender condition, to the previously announced tender offer (the “Offer”) by Genmab Holding II B.V., a wholly owned subsidiary of Genmab (“Purchaser”), to acquire all the issued and outstanding common shares of Merus N.V. (Nasdaq: MRUS) (“Merus”) for $97 per common share in cash have been satisfied. The transaction meaningfully accelerates Genmab's shift to a whol.

Business Wire • Dec 12, 2025

Genmab to Hold 2025 R&D Update and ASH Data Review Meeting

Media Release Event to be held virtually via live webcast and archived on www.genmab.com Copenhagen, Denmark; December 11, 2025 –  Genmab A/S (Nasdaq: GMAB) will hold its 2025 R&D Update and ASH Data Review Meeting today, December 11, 2025 at 11:00 AM Eastern Time (5:00 PM CET / 4:00 PM GMT). The event will take place virtually and can be attended via live webcast.

GlobeNewsWire • Dec 11, 2025

Genmab A/S (GMAB) Discusses 2025 R&D Progress, ASH Data Review, and Strategic Pipeline Additions Transcript

Genmab A/S (GMAB) Discusses 2025 R&D Progress, ASH Data Review, and Strategic Pipeline Additions Transcript

Seeking Alpha • Dec 11, 2025

These Are The 5 Best Stocks To Buy Now Or Watch

Buying a stock is easy, but buying the right stock without a good strategy is incredibly hard. Here are five top-performing stocks to buy now or put on a watchlist.

Investors Business Daily • Dec 10, 2025

Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new and updated data from three arms of the ongoing Phase 1b/2 EPCORE® CLL-1 trial (NCT04623541) evaluating the efficacy and safety of epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, as a monotherapy and in combination for the treatment of patients with Richter transformation (RT), a rare complication in which chronic lymphocytic leukemia (CLL) evolves into an aggressive lymphoma.

Business Wire • Dec 8, 2025

Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced primary data from the pivotal Phase 3 EPCORE® FL-1 study evaluating fixed duration EPKINLY® (epcoritamab-bysp) in combination with rituximab and lenalidomide (EPKINLY + R2) in adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The study showed that treatment with EPKINLY + R2 reduced the risk of disease progression or death by 79% (HR 0.21, 95% CI: 0.14-0.31, p

Business Wire • Dec 7, 2025

Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced updated results from two ongoing clinical trials evaluating the efficacy and safety of epcoritamab-bysp, a T-cell engaging antibody administered subcutaneously, as a monotherapy and in combination with other standard of care treatments in adult patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Results from two arms of the EPCORE® NHL-2 trial, evaluating first-line, fixed-treatment dur.

Business Wire • Dec 6, 2025

AI Plays Lead Five Stocks To Watch Near Buy Points

Taiwan Semiconductor leads three rebounding AI plays. Genmab and JPMorgan also are stocks to watch.

Investors Business Daily • Dec 6, 2025

How Stock Of The Day Genmab Is Leveraging An $8 Billion Deal To Stoke Its Next Chapter

Genmab stock, Thursday's IBD Stock Of The Day, is just below an early entry in a cup case after announcing an $8 billion deal to buy Merus.

Investors Business Daily • Dec 4, 2025

Genmab A/S (GMAB) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Genmab A/S (GMAB) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Seeking Alpha • Dec 4, 2025